PURPOSE: Currently, there is no clinically validated test for the prediction of response to tubulin-targeting agents in non-small cell lung cancer (NSCLC). Here, we investigated the significance of nuclear expression of the mitotic checkpoint gene checkpoint with forkhead and ringfinger domains (CHFR) as predictor of response and overall survival with taxane-based first-line chemotherapy in advanced stage NSCLC. METHODS: We studied a cohort of 41 patients (median age 63 years) with advanced NSCLC treated at the Atlanta VAMC between 1999 and 2010. CHFR expression by immunohistochemistry (score 0-4) was correlated with clinical outcome using chi-square test and Cox proportional models. A cutoff score of "3" was determined by receiver operator characteristics analysis for "low" CHFR expression. Results were validated in an additional 20 patients who received taxane-based chemotherapy at Emory University Hospital and the Atlanta VAMC. RESULTS: High expression (score = 4) of CHFR is strongly associated with adverse outcomes: the risk for progressive disease after first-line chemotherapy with carboplatin-paclitaxel was 52% in patients with CHFR-high versus only 19% in those with CHFR-low tumors (P = 0.033). Median overall survival was strongly correlated with CHFR expression status (CHFR low: 9.9 months; CHFR high: 6.2 months; P = 0.002). After multivariate adjustment, reduced CHFR expression remained a powerful predictor of improved overall survival (HR = 0.24; 95% CI, 0.1-0.58%; P = 0.002). In the validation set, low CHFR expression was associated with higher likelihood of clinical benefit (P = 0.03) and improved overall survival (P = 0.038). CONCLUSIONS: CHFR expression is a novel predictive marker of response and overall survival in NSCLC patients treated with taxane-containing chemotherapy.
PURPOSE: Currently, there is no clinically validated test for the prediction of response to tubulin-targeting agents in non-small cell lung cancer (NSCLC). Here, we investigated the significance of nuclear expression of the mitotic checkpoint gene checkpoint with forkhead and ringfinger domains (CHFR) as predictor of response and overall survival with taxane-based first-line chemotherapy in advanced stage NSCLC. METHODS: We studied a cohort of 41 patients (median age 63 years) with advanced NSCLC treated at the Atlanta VAMC between 1999 and 2010. CHFR expression by immunohistochemistry (score 0-4) was correlated with clinical outcome using chi-square test and Cox proportional models. A cutoff score of "3" was determined by receiver operator characteristics analysis for "low" CHFR expression. Results were validated in an additional 20 patients who received taxane-based chemotherapy at Emory University Hospital and the Atlanta VAMC. RESULTS: High expression (score = 4) of CHFR is strongly associated with adverse outcomes: the risk for progressive disease after first-line chemotherapy with carboplatin-paclitaxel was 52% in patients with CHFR-high versus only 19% in those with CHFR-low tumors (P = 0.033). Median overall survival was strongly correlated with CHFR expression status (CHFR low: 9.9 months; CHFR high: 6.2 months; P = 0.002). After multivariate adjustment, reduced CHFR expression remained a powerful predictor of improved overall survival (HR = 0.24; 95% CI, 0.1-0.58%; P = 0.002). In the validation set, low CHFR expression was associated with higher likelihood of clinical benefit (P = 0.03) and improved overall survival (P = 0.038). CONCLUSIONS: CHFR expression is a novel predictive marker of response and overall survival in NSCLCpatients treated with taxane-containing chemotherapy.
Authors: Priya Chaturvedi; Valery Sudakin; Matthew L Bobiak; Paul W Fisher; Michael R Mattern; Sandra A Jablonski; Mark R Hurle; Yuan Zhu; Tim J Yen; Bin-Bing S Zhou Journal: Cancer Res Date: 2002-03-15 Impact factor: 12.701
Authors: Paul G Corn; Matthew K Summers; Franz Fogt; Arvind K Virmani; Adi F Gazdar; Thanos D Halazonetis; Wafik S El-Deiry Journal: Carcinogenesis Date: 2003-01 Impact factor: 4.944
Authors: Pasi A Jänne; Alice T Shaw; José Rodrigues Pereira; Gaëlle Jeannin; Johan Vansteenkiste; Carlos Barrios; Fabio Andre Franke; Lynda Grinsted; Victoria Zazulina; Paul Smith; Ian Smith; Lucio Crinò Journal: Lancet Oncol Date: 2012-11-28 Impact factor: 41.316
Authors: Reginald V N Lord; Jan Brabender; David Gandara; Vicente Alberola; Carlos Camps; Manuel Domine; Felip Cardenal; José M Sánchez; Paul H Gumerlock; Miquel Tarón; José J Sánchez; Kathleen D Danenberg; Peter V Danenberg; Rafael Rosell Journal: Clin Cancer Res Date: 2002-07 Impact factor: 12.531
Authors: George Mariatos; John Bothos; Panayotis Zacharatos; Matthew K Summers; Daniel M Scolnick; Christos Kittas; Thanos D Halazonetis; Vassilis G Gorgoulis Journal: Cancer Res Date: 2003-11-01 Impact factor: 12.701
Authors: Lorraine Pelosof; Sashidhar R Yerram; Nita Ahuja; Andrew Delmas; Ludmila Danilova; James G Herman; Nilofer S Azad Journal: Int J Cancer Date: 2013-08-24 Impact factor: 7.396
Authors: Karen Kelly; Kari Chansky; Philip C Mack; Primo N Lara; Fred R Hirsch; Wilbur A Franklin; Antoinette J Wozniak; Martin J Edelman; Stephen K Williamson; David R Gandara Journal: Clin Lung Cancer Date: 2013-07-31 Impact factor: 4.785
Authors: Pauline M W van Kempen; Liselotte van Bockel; Weibel W Braunius; Cathy B Moelans; Marina van Olst; Rick de Jong; Inge Stegeman; Paul J van Diest; Wilko Grolman; Stefan M Willems Journal: Cancer Med Date: 2014-07-26 Impact factor: 4.452
Authors: Sarah Derks; Arjen H G Cleven; Veerle Melotte; Kim M Smits; Johann C Brandes; Nilofer Azad; Wim van Criekinge; Adriaan P de Bruïne; James G Herman; Manon van Engeland Journal: Cancer Metastasis Rev Date: 2014-03 Impact factor: 9.264
Authors: Seth A Brodie; Courtney Lombardo; Ge Li; Jeanne Kowalski; Khanjan Gandhi; Shaojin You; Fadlo R Khuri; Adam Marcus; Paula M Vertino; Johann C Brandes Journal: PLoS One Date: 2014-09-15 Impact factor: 3.240